1Weber AA, Przytulski B, Schanz A, et al. Towards a definition of aspirin resistance : a typological approach [ J ]. Platelets, 2002, 13 ( 1 ) : 37-40.
2Quick AJ. Salicylates and bleeding:The aspirin tolerance test [J]. Am J Medical Sciences, 1966,252 ( 3 ) : 265-269.
3Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs : the relationships among dose, effectiveness, and side effect [ J ]. Chest, 1998,114 [ 5Suppl ] : 470-488.
4Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane bioaynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events[ J ]. Circulation, 2002,105(14) : 1650-1655.
6Kawasaki T, Ozeki Y, lgawa T, et al. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin [ J ]. Stroke, 2000,31(3) :591.
7Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke [Jl. Stroke, 1994, 25(12) :2331-2336.
8Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease [ J ]. Am J Cardiol, 2001,88 ( 3 ) : 230-235.
9Tohgi H, Konno S, Tamura K, et al. Effects of low to high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin[ J] . Stroke, 1992,23(10) : 1400-1403.
10Hart RG, Leonard AD ,Talbert RL, et al. Aspirin dosage and thromboxane synthesis in patients with vascular disease [J]. Pharmacotherapy,2003,23(5) :579-584.
